Brain Cancer | Specialty

The OncLive Brain Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of brain cancer, including glioma, glioblastoma multiforme, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Omburtamab BLA for Pediatric Metastatic Neuroblastoma Resubmitted to FDA

April 1st 2022

A biologics license application seeking the approval of 131I-omburtamab in the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma has been resubmitted to the FDA.

Targeted Combo Notches Rare Success in Glioblastoma

March 30th 2022

Encouraging response rates to a dual-targeted regimen in patients with recurrent or refractory malignant brain tumors with BRAF V600E mutations were reported in 2021, representing a new potential targeted therapy strategy against glioblastoma.

Dr. Redjal on Technological Advances in Neurosurgical Oncology

March 26th 2022

Navid Redjal, MD, FAANS, discusses technological advances that have impacted neurosurgical oncology.

National Brain Tumor Society Launches DNA Damage Response Consortium with Yale

March 11th 2022

Consortium seeks to advance underdeveloped area of brain cancer research, advance drug development, and improve treatment options for patients

Adjuvant Neratinib Misses Primary End Point of OS in Glioblastoma, But Significantly Prolongs PFS in EGFR+ Subset

March 9th 2022

A subset of patients with EGFR-positive glioblastoma experienced significantly longer progression-free survival when treated with adjuvant neratinib following chemoradiation vs adjuvant temozolomide alone, although no overall PFS benefit or any overall survival improvement was seen in the overall population.

GLORIA Trial Examining NOX-A12 Plus Radiotherapy/Bevacizumab in Glioblastoma Safe to Continue Recruitment

January 11th 2022

The Data Safety Monitoring Board has determined that it is safe and appropriate to continue recruitment to the expansion arm of the phase 1/2 GLORIA trial, which is examining a novel combination comprised of NOX-A12, radiotherapy, and bevacizumab in glioblastoma and incomplete tumor resection.

Activating the Immune System Could be Key to Treating Pediatric Neuroblastoma

January 11th 2022

Chemoimmunotherapy is still a relatively new strategy for patients with pediatric neuroblastoma, and the humanized anti-disialoganglioside monoclonal antibody hu14.18K322A could provide a breakthrough for children with high-risk disease.

FDA Grants Fast Track Designation to ST101 for Recurrent Glioblastoma

December 6th 2021

The FDA has granted a fast track designation to ST101, a peptide antagonist of C/EBPβ, for the treatment of patients with recurrent glioblastoma.

Niraparib Trial Under Way in Newly Diagnosed Glioblastoma and Recurrent Glioma

November 8th 2021

A phase 0 trial that will evaluate niraparib in patients with newly diagnosed glioblastoma and recurrent glioma has just opened.

Tumor-Treating Fields Continues to Garner Interest in Glioblastoma

October 26th 2021

Concurrent use of tumor-treating fields, radiation therapy, and temozolomide is under study as a potential treatment for patients with newly diagnosed, stage IV glioblastoma.

Dr. Shi on the Rationale to Evaluate a Tumor-Treating Fields Therapy–Based Combination in Glioblastoma

October 25th 2021

Wenyin Shi, MD, PhD, discusses the rationale to evaluate a tumor-treating fields therapy in combination with temozolomide and radiation therapy in glioblastoma.

FDA Grants Rare Pediatric Disease Designation to 177Lu-Omburtamab-DTPA for Medulloblastoma

October 8th 2021

The FDA has granted a rare pediatric disease designation to lutetium-177-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from Y-mAbs Therapeutics, Inc., the developer of the product.

FDA Grants Orphan Drug Designation to LP-184 for Glioblastoma Multiforme and Malignant Gliomas

August 30th 2021

The FDA has granted an orphan drug designation to LP-184 as a potential therapeutic option for patients with glioblastoma multiforme and other malignant gliomas.

Silmitasertib Gets Fast Track Status for Recurrent Sonic Hedgehog–Driven Medulloblastoma

August 25th 2021

The FDA has granted a fast track designation to the highly selective CK2 inhibitor silmitasertib as a potential therapeutic option for patients with recurrent sonic hedgehog–driven medulloblastoma

Developmental Interest in Allogeneic Placenta–Derived Cell Therapies Expands

July 16th 2021

Cellular medicine could represent the next frontier in the treatment of patients with cancer and many other diseases with a high unmet need.

FDA Grants Fast Track Status to Berubicin for Recurrent Glioblastoma Multiforme

July 13th 2021

The FDA has granted a fast track designation to berubicin as a potential therapeutic option for patients with recurrent glioblastoma multiforme.

Dr. Heimberger on the Variability of Responses in Glioblastoma

June 25th 2021

Amy B. Heimberger, MD, discusses the variability of responses in glioblastoma.

Dr. Weiss on Selecting Optimal Radiation Therapy for Brain Metastases

June 25th 2021

Stephanie E. Weiss, MD, FASTRO, discusses selecting optimal radiation therapy for patients with brain metastases.

Immunotherapy Is on the Rise in Glioblastoma Treatment

June 23rd 2021

The University of Texas MD Anderson Cancer Center is pursuing several novel approaches, including viro-immunotherapy and genetically engineered natural killer cells to treat patients with glioblastoma, while also conducting tumor analysis to better comprehend the disease.

Oncolytic Virus Teserpaturev Approved in Japan for Malignant Glioma

June 11th 2021

The Japan Ministry of Health, Labour, and Welfare has granted conditional and time-limited approval to teserpaturev for the treatment of patients with malignant glioma; this is the first oncolytic virus to receive approval for use in this indication or any primary brain cancer.